Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines

@article{Troadec2015AntitumoralEO,
  title={Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines},
  author={Samuel Troadec and M{\'e}lina Blairvacq and N. Oumata and H. Galons and L. Meijer and C. Berthou},
  journal={Journal of Biomedical Science},
  year={2015},
  volume={22}
}
  • Samuel Troadec, Mélina Blairvacq, +3 authors C. Berthou
  • Published 2015
  • Medicine
  • Journal of Biomedical Science
  • BackgroundAlthough Imatinib mesylate has revolutionized the treatment of chronic myeloid leukemia, some patients develop resistance with progression of leukemia. Alternative or additional targeting of signalling pathways deregulated in Bcr-Abl-driven chronic myeloid leukemia may provide a feasible option for improving clinical response and overcoming resistance.ResultsIn this study, we investigate ability of CR8 isomers (R-CR8 and S-CR8) and MR4, three derivatives of the cyclin-dependent… CONTINUE READING
    2 Citations
    miR-125b regulates cell progression in chronic myeloid leukemia via targeting BAK1.
    • 13
    • PDF
    miR-124 downregulation leads to breast cancer progression via LncRNA-MALAT1 regulation and CDK4/E2F1 signal activation
    • 68
    • PDF

    References

    SHOWING 1-10 OF 61 REFERENCES
    Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia.
    • 59
    • PDF
    Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
    • 187
    • PDF
    In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)
    • 344
    MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
    • 523
    • PDF
    Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
    • J. Melo, C. Chuah
    • Medicine, Biology
    • Hematology. American Society of Hematology. Education Program
    • 2008
    • 55
    • PDF
    CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
    • 132
    • PDF